SCHEMBL16615386

SCHEMBL16615386

CN1CCn2c(N)nnc2C1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8034374 0.77 POLB (0.48)
SCHEMBL19454155 0.75
SCHEMBL8025433 0.75 CHRM1 (0.31)
SCHEMBL10284152 0.72 P2RX7 (0.39)
SCHEMBL21152409 0.72 P2RX7 (0.40)
SCHEMBL12233075 0.72 P2RX7 (0.39)
SCHEMBL20696187 0.72 CHRM2 (0.31)
SCHEMBL16152043 0.71 P2RX7 (0.31)
SCHEMBL14985814 0.69 P2RX7 (0.36)
SCHEMBL16281086 0.68 HPGD (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022234271-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2022-11-10 WO disclosed
WO-2015048547-A2 METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed